SCHEMBL10140767

SCHEMBL10140767

[C-]#[N+]c1ccc2[nH]c(-c3c(O)c(-c4ccc(Cl)nc4)nn3C)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PKM P14618 1/20 0.34
CCNA2 P20248 4/20 0.33
CDK2 P24941 4/20 0.33
CDK4 P11802 3/20 0.33
CCND1 P24385 3/20 0.33
CCND3 P30281 3/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CHEK1 O14757 2/20 0.33
KDR P35968 2/20 0.33
PDPK1 O15530 1/20 0.32
AMY1A P0DUB6 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.30
GUSB P08236 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140763 0.87 NPC1 (0.42) NPC1RAB9AKDM4EALDH1A1MEN1
SCHEMBL10140720 0.84 PDPK1 (0.39) NPC1RAB9AKDM4EALDH1A1MEN1
SCHEMBL10140703 0.84 CA12 (0.39) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL10172538 0.83 NPC1 (0.43) NPC1RAB9AKDM4EALDH1A1MEN1
SCHEMBL10139900 0.82 F10 (0.46) NPC1RAB9AKDM4EALDH1A1
SCHEMBL10140741 0.81 KDM4E (0.42) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL10140455 0.80 AMY1A (0.44) NPC1RAB9AKDM4EALDH1A1MEN1
SCHEMBL10140793 0.76 F9 (0.41) NPC1RAB9AKDM4EALDH1A1MEN1
SCHEMBL10140918 0.75 F10 (0.37) CDK2
SCHEMBL10140104 0.72 NPBWR1 (0.36) NPC1RAB9AKDM4EALDH1A1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 NPC1 1029/4885RAB9A 400/4885KDM4E 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.